未经证实:中部区域肾上腺髓质素原(MR-proADM)可用于败血症和呼吸道感染患者的风险分层。该研究的目的是评估现有数据,并确定COVID-19参与者的MR-proADM水平与死亡率之间的关系。
UNASSIGNED:对医学电子数据库进行了全面的文献检索,包括PubMed,WebofScience,Scopus,科克伦,以及2020年1月1日至2022年11月20日发布的相关数据的灰色文献。计算95%置信区间(CI)的平均差(MD)。
UNASSIGNED:14项研究报告了幸存者的MR-proADM水平与COVID-19患者的非幸存者。汇总分析显示,存活者组的MR-proADM水平为0.841±0.295nmol/L,而非存活者为1.692±0.761nmol/L(MD=-0.78;95CI:-0.92至-0.64;p<0.001)。
未经证实:这项研究的主要发现是COVID-19的死亡率与MR-proADM水平有关,根据这项荟萃分析。使用MR-proADM可能对分类非常有益,评估可能的治疗升级,预测治疗期间的潜在并发症或患者的显著临床恶化,并避免可能不必要的录取。然而,为了确认获得的数据,有必要开展大型前瞻性研究,以探讨MR-proADM作为COVID-19严重程度标志物的潜在诊断作用.COVID-19的关键信息似乎与MR-proADM水平相关,可用作预测患者临床病程的潜在标志物。使用MR-proADM可能有利于分类,评估可能的治疗升级,预测治疗期间的潜在并发症或患者的显著临床恶化,并避免可能不必要的录取。对于COVID-19患者,MR-proADM可能是一个很好的预后指标,因为它是内皮功能的标志物,可以预测对血管舒张和收缩之间平衡的精确影响,并降低血小板聚集抑制剂,凝血抑制剂,和纤维蛋白溶解激活剂有利于凝血因子。
Mid-regional pro-adrenomedullin (MR-proADM) is useful for risk stratification in patients with sepsis and respiratory infections. The study\'s purpose was to assess the available data and determine the association between MR-proADM levels and mortality in COVID-19 participants.
A comprehensive literature search of medical electronic databases was performed including PubMed, Web of Science, Scopus, Cochrane, and grey literature for relevant data published from 1 January 2020, to 20 November 2022. Mean differences (MD) with 95% confidence intervals (CI) were calculated.
Fourteen studies reported MR-proADM levels in survivors vs. non-survivors of COVID-19 patients. Pooled analysis showed that MR-proADM level in the survivor group was 0.841 ± 0.295 nmol/L for patients who survive COVID-19, compared to 1.692 ± 0.761 nmol/L for non-survivors (MD = -0.78; 95%CI: -0.92 to -0.64; p < 0.001).
The main finding of this study is that mortality of COVID-19 is linked to MR-proADM levels, according to this meta-analysis. The use of MR-proADM might be extremely beneficial in triaging, assessing probable therapy escalation, predicting potential complications during therapy or significant clinical deterioration of patients, and avoiding admission which may not be necessary. Nevertheless, in order to confirm the obtained data, it is necessary to conduct large prospective studies that will address the potential diagnostic role of MR-proADM as a marker of COVID-19 severity.KEY MESSAGESSeverity of COVID-19 seems to be linked to MR-proADM levels and can be used as a potential marker for predicting a patient\'s clinical course.The use of MR-proADM might be beneficial in triaging, assessing probable therapy escalation, predicting potential complications during therapy or significant clinical deterioration of patients, and avoiding admission which may not be necessary.For patients with COVID-19, MR-proADM may be an excellent prognostic indicator because it is a marker of endothelial function that may predict the precise impact on the equilibrium between vascular relaxation and contraction and lowers platelet aggregation inhibitors, coagulation inhibitors, and fibrinolysis activators in favor of clotting factors.